ESMO 2025: Top 5 Key Cancer Diagnostics Takeaways From Our Experts

1. ctDNA-based Minimal Residual Disease (MRD)

MRD testing is already established in some hematologic malignancies. ESMO 2025 showcased the growing relevance for solid tumors. New evidence validates the potential to detect relapse earlier and refine treatment decisions.
Data reinforced ctDNA's role as a critical tool for guiding therapy choices and monitoring across a range of tumor types. These included colorectal, lung, and breast cancers.
For pharma, this growing clinical confidence highlights an urgent need to build partnerships. Through synergy, consistent MRD can better integrate into clinical pathways.
A recurring theme across trials was the challenge of test sensitivity. This is a key limitation that must be addressed to enable clinical adoption of ctDNA-based MRD.
Collaboration between pharma, labs, and diagnostic partners is crucial in closing this gap. Diaceutics leverages real-time lab data to uncover where testing readiness exists. And where barriers persist. Through targeted expert engagement and peer-to-peer physician education, we help translate diagnostic insights into action. This helps ensure testing drives confident prescribing and faster adoption of precision therapies.

2. Ovarian cancer with high unmet need shows promising treatment

Antibody-drug conjugates (ADCs) were a defining theme again this year. Promising new data in ovarian cancer are driving optimism for improved outcomes in prognostic populations. FRα-directed ADCs continued to prove strong efficacy signals. And it is positioning this class as a leading area of innovation.
Competitive differentiation will depend not only on efficacy, but on precision where relevant. This ensures eligible patients are identified early.
Our data-driven insights help pharma identify two core areas. Firstly, it shows where testing gaps exist. Secondly, how to accelerate biomarker adoption pre-launch. Combined, this ensures new ADC innovations can reach the right patients faster.

3. Lung cancer: evolving complexity in a crowded biomarker space

Metastatic NSCLC continues to illustrate the complexity of precision oncology. A high number of actionable targets already exist in this arena.
Anti-HER2 therapies are now likely moving into first-line treatment. HER2 testing is expected to be smoothly implemented. However, the education of labs and oncologists remains essential to ensure consistent adoption.
Pharma teams must look beyond drug development to ensure that testing patterns in the real world reflect the molecular sophistication of modern trials. Fragmented data and inconsistent testing remain key barriers to full adoption.
Our precision testing data reveal where real-world gaps persist. This empowers pharma to align educational efforts and optimize launch based on testing behavior. And not just trial design.

4. Bladder cancer: potential changes in standard of care in early and metastatic settings

New results in urothelial carcinoma continue to build on the success of combination regimens such as HER2-directed plus immunotherapy. This is driving enthusiasm for improved patient outcomes.
ESMO 2025 signaled potential shifts in the standard of care for both early and metastatic disease. It highlighted how combination strategies are becoming more central to the future of bladder cancer treatment.
Combination approaches will redefine treatment pathways. But this will only happen if testing strategies evolve alongside them. Pharma must collaborate closely with cancer diagnostics partners. It will be essential to align biomarkers with the pace of clinical practice.
By mapping real-world biomarker utilization, we're helping pharma understand how testing behavior influences therapy uptake. This is a critical component for successful commercialization in the era of combination oncology.

5. Breast cancer: beyond HER2 – a future defined by biomarker diversity

ESMO 2025 highlighted continued progress in HER2-positive and HER2-low subtypes in breast cancer. This is alongside early signals for novel molecular targets. Beyond HER2, ADC innovation and exploration of new biomarker-driven strategies. This signals an increasingly diverse and data-led future for breast cancer treatment.

Closing remarks on ESMO 2025 and cancer diagnostics

Pharma organizations must expect more nuanced testing algorithms. And it will be key to ensure alignment between cancer diagnostics development and clinical execution. Commercial success will depend on education, accessibility, and early stakeholder engagement.
Through our global lab network and data-driven solutions, we enable companies to evolve how they test. And this empowers more effective launches in increasingly stratified therapeutic markets.

ESMO 2025 reaffirmed that the future of cancer diagnostics and oncology treatment lies in precision. But precision demands readiness. For pharma and biotech, success will hinge on translating complex science into actionable strategies. And these must improve cancer diagnostics, testing, access, and ultimately, patient outcomes.